journey to change

NHS
Tees, Esk and Wear Valleys
NHS Foundation Trust

Lurasidone (Latuda®)

Prescribing Support Series - 1

Licensed indication: The treatment of schizophrenia in adults and adolescents aged 13 years and over.

Usual dose: 37 - 148 mg once daily (max.74 mg daily in under-18s), swallowed whole, **with an evening meal of at least 350 kcal** (this optimises absorption) - see Choice & Medication for a patient information leaflet.

Recent changes to regional guidance: In September 2021, the Northern (NHS) Treatment Advisory Group (NTAG) reviewed its original appraisal (April 2015) of Lurasidone for the treatment of schizophrenia in adults, to include the license extension to use in adolescents aged 13 years and over. NTAG now recommends the use of lurasidone, for its licensed indication, in line with the criteria in the box below.

Formulary Status:

Amber Specialist Initiation – **for its licensed indication, in line with NTAG criteria (see below)**

Purple - **all** other indications; requires application for approval by panel; approval by lead psychiatrist alone for bipolar depression on recommendation of RADs; prescribing & monitoring responsibility must not transfer **(red)**

NTAG criteria for prescribing Lurasidone for the treatment of schizophrenia in adults & adolescents aged 13 years & older who require an antipsychotic:

- Patients who have not responded to or not tolerated aripiprazole, **and**
- where the patient does not fulfil the treatment resistance criteria as outlined in NICE Clinical Guideline 178 for the initiation of prescribing of clozapine, **and**
- who fulfil one of the following criteria:
  - Clinically significant weight gain on other antipsychotics (defined as greater than or equal to 5% gain in weight from baseline after a month of treatment)
  - Presence of a clinical condition that makes avoidance of weight gain and metabolic adverse effects of particular importance, e.g., diabetes, cardiovascular disease
  - Patients with a prolonged QTc interval

Interactions

Contra-indicated with:

- strong CYP3A4 Inhibitors, e.g. clarithromycin (significant increase in lurasidone serum levels)
- strong CYP3A4 inducers, e.g. carbamazepine, rifampicin, St John's wort (significant reduction in lurasidone serum levels)

Avoid:

- Grapefruit juice - may increase lurasidone serum levels

Caution when used with:

- moderate CYP3A4 inhibitors, e.g. erythromycin (may increase lurasidone serum levels)
- mild / moderate CYP3A4 inducers, e.g. prednisolone, modafinil (lurasidone dose adjustments may be necessary due to reduced serum levels)
- alcohol and other centrally acting drugs
- other serotonergic drugs (risk of serotonin syndrome
- drugs likely to prolong QT interval

Cost (October 2022 Drug Tariff):

18.5 mg tablets £39.60/28
37 mg tablets £39.60/28
74 mg tablets £39.60/28
Max 148 mg/day = 2 x 74 mg = £79.20/28 days

Adverse effects:

Most common (thought to be dose-related): Akathisia and somnolence

Other common effects: Insomnia, agitation, anxiety, restlessness, parkinsonism, dystonia, dizziness, dyskinesia, increased weight, hypersensitivity, nausea, vomiting, dyspepsia, salivary hypersecretion, dry mouth, rash.

Refer to SPC for full prescribing information

Title	Prescribing Support Series 1 - Lurasidone
Approved	26th May 2022
Review by	1st June 2025

To obtain a more accessible version of this document, please send an email to: Tewv.pharmacyadmin@nhs.net